{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T16:24:36Z","timestamp":1649003076440},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12325-021-01679-w","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T12:58:49Z","timestamp":1615294729000},"page":"8-15","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["American Society of Hematology 2020 Podcast Collection: FL and DLBCL"],"prefix":"10.1007","volume":"38","author":[{"given":"Christopher Paul","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"crossref","unstructured":"Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136834.html.","DOI":"10.1182\/blood-2020-135871"},{"key":"1679_CR2","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al. Efficacy and safety of tisagenlecleucel in adult patients with relapsed\/refractory follicular lymphoma: interim analysis of the phase 2 Elara trial. ASH 2020 conference. 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper138983.html."},{"key":"1679_CR3","unstructured":"Ramakrishnan A, Ardeshna KM, Batlevi CL, et al. Phase 1 Alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL. ASH 2020 conference. 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper133960.html."},{"key":"1679_CR4","doi-asserted-by":"crossref","unstructured":"Borchmann P, J\u00fchling A, G\u00f6del P, et al. Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell non-hodgkin lymphoma. ASH 2020 conference. 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136067.html.","DOI":"10.1182\/blood-2020-136067"},{"key":"1679_CR5","doi-asserted-by":"crossref","unstructured":"Cao Y, Xiao Y, Wang N, et al. D19\/CD22 CAR-T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory B-cell lymphomas. ASH 2020 conference. 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper140308.html.","DOI":"10.1182\/blood-2020-140308"},{"key":"1679_CR6","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Dickinson S, Ulrickson ML, et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). ASH 2020 conference. 2020. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper134449.html.","DOI":"10.1182\/blood-2020-134449"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01679-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01679-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01679-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T15:09:04Z","timestamp":1624806544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01679-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":6,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01679-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}